BioLineRx Ltd. (BLRX)

Market Cap	11.75M +15.3%
Revenue (ttm)	1.18M -95.9%
Net Income	-1.18M
EPS	-0.00
Shares Out	2.61B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,391
Open	2.920
Previous Close	2.860
Day's Range	2.871 - 3.060
52-Week Range	2.150 - 7.770
Beta	0.59
Analysts	Strong Buy
Price Target	17.50 (+471.9%)
Earnings Date	May 27, 2026

About BLRX

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2011
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: BLRX
• Website: https://www.biolinerx.com

Financial Performance

In 2025, BioLineRx's revenue was $1.18 million, a decrease of -95.92% compared to the previous year's $28.94 million. Losses were -$1.18 million, -87.26% less than in 2024.

Analyst Summary

According to one analyst, the rating for BLRX stock is "Strong Buy" and the 12-month stock price target is $17.5.

Price Target

$17.5

(471.90% upside)

Analyst Consensus: Strong Buy